22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › HALOZYME THERAPEUTICS INC. › 2024-2025

HALOZYME THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and HALOZYME THERAPEUTICS INC.’s Form 8-K, filed May 2, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 512Asset managers, any item
  • 2,632Fund votes
  • May 1, 2025Meeting date

Results at a glance

Meeting of May 1, 2025: 4 items on HALOZYME THERAPEUTICS INC.’s Form 8-K, filed May 2, 2025: 2 approved · 2 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore HALOZYME THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by HALOZYME THERAPEUTICS INC.

These tallies are HALOZYME THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 2, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

HALOZYME THERAPEUTICS INC. — official shareholder meeting results, meeting held May 1, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jeffrey W. Henderson 98,993,4633,298,11795,045 --10,380,378 97%Passed (calculated)—
Elect Director: Helen I. Torley 101,477,199816,67592,751 --10,380,378 99.2%Passed (calculated)—
2. Advisory vote on the compensation of the Company's named executive officers 98,252,4643,966,034168,127 --10,380,378 96%Approved—
3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 112,028,211659,97678,816 ---- 99.4%Approved—

Source: HALOZYME THERAPEUTICS INC., Form 8-K, filed with the SEC on May 2, 2025 — read the filing on EDGAR.

How asset managers voted at the HALOZYME THERAPEUTICS INC. 2024-2025 meeting

512 asset managers disclosed a vote on at least one HALOZYME THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Helen I. Torley

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%
FOR: 101,477,199AGAINST: 816,675
Details: description as filed, official tally, votes by 136 asset managers

Description as filed by funds: Election of Class III Directors: Helen I. Torley

HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Helen I. Torley”): 101,477,199 for, 816,675 against, per its Form 8-K filed May 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 136 asset managers below reported 56,859,508 for, 62,375 against, 46,609 abstained.

FOR
FOR: 56,859,508AGAINST: 62,375ABSTAIN: 46,609
Largest asset managers voting on “Election of Class III Directors: Helen I. Torley” at HALOZYME THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard14,665,2450 00For
BlackRock9,674,7280 00For
Fidelity3,221,1940 00For
State Street3,087,2400 00For
Invesco2,072,3220 00For
Delaware/Macquarie1,970,9390 00For
Charles Schwab1,756,6730 00For
Dimensional1,435,5500 00For
TIAA1,297,0970 00For
JPMorgan1,112,3230 00For
T. Rowe Price894,9360 00For
First Trust797,5310 00For
Capital Group748,2300 00For
Capitol Series Trust725,8550 00For
American Century724,7020 00For
AllianceBernstein705,1550 00For
Putnam653,9050 00For
Equitable637,7510 00For
Artisan468,3380 00For
PROFESSIONALLY MANAGED PORTFOLIOS456,7420 00For
Victory Capital422,2520 00For
Jackson National403,4860 00For
GLENMEDE FUND INC386,5310 00For
AB DISCOVERY GROWTH FUND, INC.378,1600 00For
BOSTON TRUST WALDEN FUNDS359,8760 00For

Showing the 25 largest of 136 asset managers. All 136 are in the interactive database (link above).

Elect Director: Jeffrey W. Henderson

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 98,993,463AGAINST: 3,298,117
Details: description as filed, official tally, votes by 136 asset managers

Description as filed by funds: Election of Class III Directors: Jeffrey W. Henderson

HALOZYME THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey W. Henderson”): 98,993,463 for, 3,298,117 against, per its Form 8-K filed May 2, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 136 asset managers below reported 55,571,372 for, 1,236,011 against, 46,609 abstained.

FOR
FOR: 55,571,372AGAINST: 1,236,011ABSTAIN: 46,609
Largest asset managers voting on “Election of Class III Directors: Jeffrey W. Henderson” at HALOZYME THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard14,665,2450 00For
BlackRock9,674,7280 00For
Fidelity3,221,1940 00For
State Street3,087,2400 00For
Invesco2,072,3220 00For
Delaware/Macquarie1,970,9390 00For
Charles Schwab1,756,6730 00For
Dimensional1,435,5500 00For
TIAA1,297,0970 00For
JPMorgan1,112,3230 00For
T. Rowe Price0894,936 00Against
First Trust797,5310 00For
Capital Group748,2300 00For
Capitol Series Trust725,8550 00For
American Century724,7020 00For
AllianceBernstein705,1550 00For
Putnam653,9050 00For
Equitable637,7510 00For
Artisan468,3380 00For
PROFESSIONALLY MANAGED PORTFOLIOS456,7420 00For
Victory Capital422,2520 00For
Jackson National403,4860 00For
GLENMEDE FUND INC386,5310 00For
AB DISCOVERY GROWTH FUND, INC.378,1600 00For
BOSTON TRUST WALDEN FUNDS359,8760 00For

Showing the 25 largest of 136 asset managers. All 136 are in the interactive database (link above).

Advisory vote on the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 13 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 98,252,464AGAINST: 3,966,034

Prior year: 97.9% for (April 25, 2024 meeting) ▼ 1.8 pts

Details: description as filed, official tally, votes by 509 asset managers

Description as filed by funds: To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.

HALOZYME THERAPEUTICS INC.’s own tally for this item (“2. The advisory vote on the compensation of the Company's named executive officers”): 98,252,464 for, 3,966,034 against — passed, per its Form 8-K filed May 2, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 133 asset managers voting on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.” at HALOZYME THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard14,665,2450 00For
BlackRock9,674,7280 00For
Fidelity3,221,1940 00For
State Street3,087,2400 00For
Invesco02,072,322 00Against
Delaware/Macquarie1,970,9390 00For
Charles Schwab1,756,6730 00For
Dimensional1,435,5500 00For
TIAA1,297,0970 00For
JPMorgan1,112,3230 00For
T. Rowe Price894,9360 00For
First Trust797,5310 00For
Capital Group748,2300 00For
Capitol Series Trust725,8550 00For
American Century724,7020 00For
AllianceBernstein705,1550 00For
Putnam653,9050 00For
Equitable637,7510 00For
Artisan468,3380 00For
PROFESSIONALLY MANAGED PORTFOLIOS456,7420 00For
Victory Capital422,2520 00For
Jackson National403,4860 00For
GLENMEDE FUND INC386,5310 00For
AB DISCOVERY GROWTH FUND, INC.378,1600 00For
BOSTON TRUST WALDEN FUNDS359,8760 00For

Fund voting reports, all 133 managers: 54,459,586 for, 2,413,515 against, 46,609 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 416 asset managers voting on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.” at HALOZYME THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
State Street6,490,6420 00For
BlackRock4,907,930997 00For
SNYDER CAPITAL MANAGEMENT L P3,463,9370 00For
GEODE CAPITAL MANAGEMENT, LLC3,093,1920 00For
AllianceBernstein3,061,8460 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST2,576,5680 00For
Invesco02,232,464 00Against
JPMorgan2,098,2310 00For
Charles Schwab1,782,2140 00For
GW&K Investment Management, LLC1,536,1780 00For
CONGRESS ASSET MANAGEMENT CO1,527,3460 00For
ArrowMark Colorado Holdings LLC1,466,0430 00For
Nuveen1,459,5690 00For
T. Rowe Price1,234,6430 00For
Stephens Investment Management Group LLC1,096,5310 00For
FULLER & THALER ASSET MANAGEMENT, INC.1,061,5990 00For
Northern Trust1,028,1700 00For
MELLON INVESTMENTS Corp985,1060 00For
Artisan851,6600 00For
Epoch Investment Partners, Inc.839,3900 00For
American Century753,3230 00For
Capital Group748,6660 00For
Putnam712,3170 00For
Janus Henderson648,2980 00For
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC638,5070 00For

Institutional-manager reports, all 416 managers: 59,583,137 for, 3,192,883 against, 52,687 abstained, 5,072 not voted, 61 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%
FOR: 112,028,211AGAINST: 659,976

Prior year: 99.4% for (April 25, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 136 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

HALOZYME THERAPEUTICS INC.’s own tally for this item (“3. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 112,028,211 for, 659,976 against — passed, per its Form 8-K filed May 2, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 136 asset managers below reported 56,920,151 for, 724 against, 46,609 abstained.

FOR
FOR: 56,920,151AGAINST: 724ABSTAIN: 46,609
Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm fo” at HALOZYME THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard14,665,2450 00For
BlackRock9,674,7280 00For
Fidelity3,221,1940 00For
State Street3,087,102138 00For
Invesco2,072,3220 00For
Delaware/Macquarie1,970,9390 00For
Charles Schwab1,756,6730 00For
Dimensional1,435,5500 00For
TIAA1,297,0970 00For
JPMorgan1,112,3230 00For
T. Rowe Price894,9360 00For
First Trust797,5310 00For
Capital Group748,2300 00For
Capitol Series Trust725,8550 00For
American Century724,7020 00For
AllianceBernstein705,1550 00For
Putnam653,9050 00For
Equitable637,7510 00For
Artisan468,3380 00For
PROFESSIONALLY MANAGED PORTFOLIOS456,7420 00For
Victory Capital422,2520 00For
Jackson National403,4860 00For
GLENMEDE FUND INC386,5310 00For
AB DISCOVERY GROWTH FUND, INC.378,1600 00For
BOSTON TRUST WALDEN FUNDS359,8760 00For

Showing the 25 largest of 136 asset managers. All 136 are in the interactive database (link above).

Largest HALOZYME THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 123,170,000 shares outstanding at the time of that meeting.

Fund voting reports: top HALOZYME THERAPEUTICS INC. shareholders by shares voted on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 11.91%
2BlackRock 7.85%
3Fidelity 2.62%
4State Street 2.51%
5Invesco 1.68%
6Delaware/Macquarie 1.60%
7Charles Schwab 1.43%
8Dimensional 1.17%
9TIAA 1.05%
10JPMorgan 0.90%
Institutional-manager reports: top HALOZYME THERAPEUTICS INC. shareholders by shares voted on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1State Street 5.27%
2BlackRock 3.99%
3SNYDER CAPITAL MANAGEMENT L P 2.81%
4GEODE CAPITAL MANAGEMENT, LLC 2.51%
5AllianceBernstein 2.49%
6MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST 2.09%
7Invesco 1.81%
8JPMorgan 1.70%
9Charles Schwab 1.45%
10GW&K Investment Management, LLC 1.25%

Reported HALOZYME THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

HALOZYME THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock17,092,111 13.88%Form 13F, quarter ended March 31, 2025
Vanguard Group12,831,503 10.42%Form 13F, quarter ended March 31, 2025
STATE STREET CORPORATION6,053,007 4.91%Schedule 13G, filed May 13, 2025
Invesco3,894,297 3.16%Form 13F, quarter ended March 31, 2025
Helen I. Torley2,505,521 2.03%Proxy statement (DEF 14A), table as of March 4, 2025
JPMorgan Chase2,474,825 2.01%Form 13F, quarter ended March 31, 2025
Dimensional Fund Advisors2,029,160 1.65%Form 13F, quarter ended March 31, 2025
Morgan Stanley1,931,474 1.57%Form 13F, quarter ended March 31, 2025
Charles Schwab1,748,851 1.42%Form 13F, quarter ended March 31, 2025
Northern Trust1,740,281 1.41%Form 13F, quarter ended March 31, 2025

Percentages above are of 123,170,000 shares outstanding, as reported by HALOZYME THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At HALOZYME THERAPEUTICS INC.'s shareholder meeting held May 1, 2025, in the 2024-2025 proxy season, 512 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 2,632 separate fund positions. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — HALOZYME THERAPEUTICS INC.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: HALOZYME THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 2, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from HALOZYME THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

HALOZYME THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “HALOZYME THERAPEUTICS (HALO) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/halozyme-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.